Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06870240 is not yet recruiting (as of Apr 2026), with site activation just starting in Mar 2026 and primary completion est. Jan 2027. No results or readout available; all sources confirm pre-enrollment stage, projecting data in late 2026.
Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed95% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial is not yet recruiting (estimated primary completion Jan 2026, final readout ~Q4 2026). No results, interim data, or efficacy readouts published. All sources discuss only startup, Phase 1 safety, and future plans.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
NO_DECISIONDismissed97% confidencemanual-chat-review
Will the results be positive?
Oragenics still described ONP-002 as a Phase IIa study moving through site activation and preparing for enrollment, so there is no trial readout yet to score as positive or negative.
Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:33 PM
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 efficacy readout is public yet. Sponsor updates in Feb-Mar 2026 say the study was still initiating sites / preparing for enrollment and that final Phase 2a readout is expected in Q4 2026. With no results disclosed, the outcome cannot be classified positive or negative.
Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:20 PM
NO_DECISIONDismissed98% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 readout is public yet. The cited sources show this exact ONP-002 Phase 2a study was only cleared to commence in March 2026, and the sponsor says interim data are expected during 2026 with final readout in Q4 2026. That is insufficient to call positive or negative now.
Found Apr 2, 2026, 5:14 PMReviewed Apr 3, 2026, 4:48 PM
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific efficacy readout is publicly available. Sponsor materials in Nov 2025 still described Phase IIa readout as a 2026 future milestone, and on Mar 12, 2026 the company said site activation was underway with enrollment/patient dosing next. Registry-derived listing shows the study as not yet recruiting.
Found Mar 31, 2026, 9:41 PMReviewed Apr 1, 2026, 6:35 AM
Sponsororagenics.comMar 12, 2026, 12:00 AM
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Company said first site initiation was completed; remaining sites were in final review, with patient enrollment and dosing to begin shortly. This indicates no Phase 2a outcome data/readout yet.
Sponsorbusinesswire.comNov 11, 2025, 12:00 AM
Oragenics Q3 2025 Shareholder Update
The update listed Phase IIa initiation as a near-term catalyst and Phase IIa data readout as a 2026 goal, showing that results were still pending at that time.
ClinicalTrialsichgcp.netMar 10, 2025, 12:00 AM
Neurosteroid enantiomer in Mild Traumatic Brain Injury, Concussion - Clinical Trials Registry - ICH GCP
Registry page for NCT06870240, sourced from ClinicalTrials.gov, lists study status as 'Not yet recruiting,' with no posted results.
NO_DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public efficacy readout is evident for this exact Phase 2 trial. The cited trial-specific registry mirror still lists NCT06870240 as not yet recruiting, and Oragenics said on March 11, 2026 that Phase IIa was only in active site initiation, with sites still completing governance reviews before patient enrollment. That means there is not enough trial-specific public results evidence to classify the readout as positive or negative.
Found Mar 30, 2026, 4:24 AMReviewed Mar 30, 2026, 4:31 AM
Web Searchbiotechhunter.com
NCT06870240 - A Randomised, Double-blind, Placebo-controlled Phase 2a Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONP-002 in Adults With Mild Traumatic Brain Injury
This trial-specific page for NCT06870240 lists the study as Phase 2, not yet recruiting, with primary completion date January 1, 2026 and study completion date March 31, 2026.
Sponsorir.oragenics.comMar 11, 2026, 12:00 AM
Oragenics explores expansion of CNS platform pursuing acquisition of assets in brain health, recovery, and neuroprotection
Oragenics stated: The Phase IIa clinical trial of ONP-002 is now in active site initiation, with the first site initiation visit completed in Australia and two additional sites in Australia completing final Research Governance reviews prior to patient enrollment.
Sponsororagenics.com
Pipeline
On Oragenics' pipeline page, ONP-002 for concussion is shown with Phase 2 marked as phase not started, and the company says it is currently preparing the launch of a Phase II clinical study.